What Pharmacists Need to Know about OIC: Practical Approaches in Assessment and Management
Activity Post Test and Evaluation Form

Post Test

Please note that to receive credit you must achieve a score of at least 70%.

Pharmacists: The information that you participated will be uploaded to CPE Monitor and you will be able to access your credits from the profile you set up with NABP. For more information, please visit http://www.nabp.net/.

Question Title

* 1. Ideally, patients receiving opioid medications should be counseled about OIC risk and prevention:

Prior to initiating opioid treatment

At the first follow-up visit

At the first signs of constipation

Depends on the prescribed opioid

Question Title

* 2. Opioid effects on the gastrointestinal system include all of the following except:

Decreases GI motility

Increases intestinal secretion

Increases absorption of fluid from gut

Decreases defecation reflex

Question Title

* 3. Which of the following laxatives primarily acts as a bulking agent?

Psyllium

Senna

Docusate

Magnesium sulfate

Question Title

* 4. Which of the following is not a peripherally-acting mu-opioid receptor antagonist (PAMORA)?

Methylnaltrexone

Naloxegol

Lubiprostone

Naldemedine

Question Title

* 5. A 67-year-old man who is receiving oxycodone for low back pain complains of severe constipation for the past 2 weeks consisting of straining, excessive time on the toilet, and a feeling of incomplete bowel emptying. He has tried OTC laxatives with inadequate response. He says that sometimes he has to take an extra dose of oxycodone to manage pain. An appropriate next step for this patient is:

Switch pain treatment to methadone

Prescribe a stimulant laxative

Suggest reducing his oxycodone dose by 50%

Initiate treatment with a PAMORA